Overview

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

Status:
Not yet recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjunctivitis
Phase:
Phase 4
Details
Lead Sponsor:
Clinical Research Center of Florida
Collaborator:
Ocular Therapeutix, Inc.
Treatments:
Dexamethasone
Loteprednol Etabonate
Olopatadine Hydrochloride
Ophthalmic Solutions